PWPCM
SAGE

Perella Weinberg Partners Capital Management’s Sage Therapeutics SAGE Stock Holding History

Perella Weinberg Partners Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-41,986
Closed -$888K – 66
2015
Q4 		$888K Buy
+41,986
New +$2.08M 0.3% 40

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Perella Weinberg Partners Capital Management's SAGE Position: Q1 2016 in Review

Perella Weinberg Partners Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2016, closing a stake of 41,986 shares — an estimated $888K sold.

Perella Weinberg Partners Capital Management first reported a position in SAGE in Q4 2015 and held it in 1 quarter. The position peaked at $888K in Q4 2015. 144 funds tracked by Wall St. Rank hold SAGE as of Q1 2016.

  • Perella Weinberg Partners Capital Management reported no remaining Sage Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Perella Weinberg Partners Capital Management sold 41,986 Sage Therapeutics shares in Q1 2016, an estimated $888K.
  • Perella Weinberg Partners Capital Management first reported a position in Sage Therapeutics in Q4 2015 and held it in 1 quarter.
  • Perella Weinberg Partners Capital Management's Sage Therapeutics position peaked at $888K in Q4 2015.
  • 144 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2016.

Based on Perella Weinberg Partners Capital Management's 13F filing for Q1 2016, filed 16 May 2016.